ABCL - CIK 0001703057
AbCellera Biologics Inc. (ABCL) reported revenue of $75.13M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $75.13M | +160.6% |
| FY 2024 | $28.83M | -24.2% |
| FY 2023 | $38.02M | -92.2% |
| FY 2022 | $485.42M | +29.4% |
| FY 2021 | $375.20M | +60.9% |
| FY 2020 | $233.16M | +1907.9% |
| FY 2019 | $11.61M | - |
AbCellera Biologics Inc. (ABCL) reported revenue of $75.13M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, AbCellera Biologics Inc.'s revenue grew from $11.61M to $75.13M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.